Protein Expression News and Research

RSS

APC-300 drug significantly inhibits pancreatic cancer cell growth: Adamis

Adamis Pharmaceuticals Corporation announced today that in addition to its activity in prostate cancer, its drug APC-300 significantly inhibits the growth of pancreatic cancer cells.

25 Mar 2011

New study provides insights into epiboly mechanisms linked with wound healing, cancer

Avian embryos could join the list of model organisms used to study a specific type of cell migration called epiboly, thanks to the results of a study published this month in the journal Developmental Dynamics.

24 Mar 2011

Vical receives EMA Scientific Advice for Phase 3 trial of TransVax therapeutic CMV vaccine

Vical Incorporated announced today the receipt of Scientific Advice from the European Medicines Agency (EMA) recommending practical efficacy endpoints for a Phase 3 trial of the company's TransVax™ therapeutic cytomegalovirus (CMV) vaccine.

3 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

EPO grants three core patents to caprotec's CCMS technology

caprotec bioanalytics GmbH announced today that the European Patent Office has granted the last of three core patents protecting its proprietary and revolutionary Capture Compound Mass Spectrometry technology.

28 Feb 2011

Scientists find p27Kip1 protein expression in adult and aged human inner ear

In collaboration with scientists and clinicians from the University of California Los Angeles, scientists from Sound Pharmaceuticals have found p27Kip1 to be expressed in the adult and aged human inner ear including the auditory and vestibular sensory organs.

25 Feb 2011

Ibio acquires Orphan Drug Designation and Fabry disease therapeutic program from Kentucky

iBio, Inc. today announced it has acquired Orphan Drug Designation for plant-produced human alpha galactosidase A and related property rights from an affiliate of Kentucky Bioprocessing LLC and has initiated a program, based on its iBioLaunch platform, to develop an improved version of the enzyme for therapy of Fabry disease.

23 Feb 2011

ETH scientists warn about impact of cell phone radiation in brain of healthy adults

Expert scientists working with Environmental Health Trust, a nonprofit research and educational group, say that new studies showing that cell phone radiation excites the brain strengthen the need for a major research program on cell phones and health, revamping approaches to setting standards, and putting warnings on cell phones.

23 Feb 2011

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix BioTherapeutics, Inc., announced today that new clinical data from the switchover trial of taliglucerase alfa in Gaucher disease patients and preclinical data on oral enzyme glucocerebrosidase (oral GCD) will be presented today at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 in Las Vegas, Nevada.

19 Feb 2011

Biocare, HJF sign license agreement to distribute antibody against prostate cancer

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has signed a licensing agreement with Biocare Medical, a biotechnology company based in Concord, Calif., for the exclusive worldwide sales and distribution rights for the immunohistochemistry of an antibody designed to detect tumor prevalence in prostate cancer patients.

18 Feb 2011

USPTO issues two patents to VIRxSYS SMaRT RNA platform technology

VIRxSYS Corporation, a privately-held biotechnology company with proprietary RNA payload and lentiviral vector delivery platform technologies, today announced that the United States Patent and Trademark Office has issued the Company two patents for its SMaRT RNA platform technology, capable of reprogramming or repairing genes to create, increase or change protein expression.

18 Feb 2011

Pfenex enters strategic agreement with Boehringer Ingelheim for use of Expression Technology

Pfenex Inc., an industry leader in protein expression through the Pfenex Expression Technology platform and Boehringer Ingelheim International GmbH, a leading pharmaceutical company and global leader in biopharmaceutical contract development and manufacture, announced today that they have entered into a strategic agreement.

16 Feb 2011

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in the scientific journal Human Vaccines.

7 Feb 2011

First commercially available full length human MTOR protein with superior biological activity released

OriGene Technologies, Inc., a gene-centric life sciences company, releases the first commercially available full length human MTOR protein with superior biological activity.

2 Feb 2011

Agilent Technologies launches AssayMAP Bravo for protein purification

Agilent Technologies today announced the launch of the AssayMAP Bravo platform and protein purification cartridges, a fully automated solution for high-throughput protein sample preparation and purification.

1 Feb 2011

Researchers examine brain's role in breathing

Much of our knowledge of the brain's role in regulating breathing comes from research with mice and rats. A chemical receptor within the brain stem communicates with the central nervous system to generate the basic pattern of breathing. The next step is applying that information to human tissue to identify these critical components in the human brain and their medical implications.

21 Jan 2011

PAM50 test is now available to classify breast cancer subtypes

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced the availability of a new laboratory developed test designed to classify breast cancer into clinically significant molecular subtypes that are important for the management of the disease.

18 Jan 2011

Study to identify early warning biomarkers for presence of breast and prostate cancers

Using biological samples taken from patients and state-of-the-art biochemical techniques, a Florida State University researcher is working to identify a variety of "biomarkers" that might provide earlier warnings of the presence of breast and prostate cancers.

11 Jan 2011

Scientists tweak gene to mimick heart-strengthening effects of endurance training in sedentary mice

By tweaking a single gene, scientists have mimicked in sedentary mice the heart-strengthening effects of two weeks of endurance training, according to a report from Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center (BIDMC).

24 Dec 2010

Zenobia, Lundbeck enter research collaboration for LRRK2 Parkinson's disease target

Zenobia Therapeutics, Inc. the leader in fragment-based lead discovery for CNS diseases, announced today a research collaboration with H. Lundbeck A/S utilizing Zenobia's expertise in protein expression and x-ray crystallography for the Parkinson's disease target, LRRK2. Under the agreement, Zenobia will continue to use its capabilities in fragment-based lead discovery (FBLD) to advance its internal LRRK2 drug discovery program independently of Lundbeck.

16 Dec 2010